Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27715512 | 0.90 | PLK1 (0.68) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL4439740 | 0.84 | CYP19A1 (0.74) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL8355017 | 0.84 | ABCG2 (0.56) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL663034 | 0.82 | ESR1 (0.80) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL31173123 | 0.80 | PLK1 (1.00) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL12068882 | 0.80 | PLK1 (1.00) | PLK1MEN1MAPTKMT2APOLB | |
| Demethoxymatteucinol SCHEMBL664144 | 0.79 | ABCG2 (0.64) | PLK1MEN1MAPTKMT2APOLB | |
| Demethoxymatteucinol SCHEMBL29204370 | 0.79 | ABCG2 (0.64) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL17931658 | 0.79 | MEN1 (0.58) | PLK1MEN1MAPTKMT2APOLB | |
| SCHEMBL9063227 | 0.79 | CYP19A1 (0.70) | PLK1MEN1MAPTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111093842-B | Adhesive films, tapes, and methods comprising (meth) acrylate matrices with curable epoxy/thiol resin compositions | 3M创新有限公司 | 2023-03-10 | — | — | CN | claimed |
| US-20200208020-A1 | ADHESIVE FILM INCLUDING A (METH)ACRYLATE MATRIX INCLUDING A CURABLE EPOXY/THIOL RESIN COMPOSITION, TAPE, AND METHOD | 3M INNOVATIVE PROPERTIES COMPANY | 2020-07-02 | — | — | US | claimed |
| CN-111093842-A | Adhesive films, tapes, and methods comprising (meth) acrylate matrices with curable epoxy/thiol resin compositions | 3M创新有限公司 | 2020-05-01 | — | — | CN | claimed |
| WO-2019053646-A1 | ADHESIVE FILM INCLUDING A (METH)ACRYLATE MATRIX INCLUDING A CURABLE EPOXY/THIOL RESIN COMPOSITION, TAPE, AND METHOD | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2019-03-21 | — | — | WO | claimed |
| EP-2268689-A1 | ADDUCTS AND CURABLE COMPOSITIONS USING SAME | Loctite (R & D) Limited (IE) | 2011-01-05 | — | — | EP | claimed |
| US-7847034-B2 | Adducts and curable compositions using same | LOCTITE (R&D) LIMITED (IE) | 2010-12-07 | — | — | US | claimed |
| US-20090240003-A1 | Adducts and Curable Compositions Using Same | LOCTITE (R&D) LIMITED (IE) | 2009-09-24 | — | — | US | claimed |
| WO-2009115586-A1 | ADDUCTS AND CURABLE COMPOSITIONS USING SAME | LOCTITE (R & D) LIMITED (IE) | 2009-09-24 | — | — | WO | claimed |
| US-20070160688-A1 | Use of flavonoids to increase blood serum levels of dehydroepiandrosterone | PROPRIETARY WELLNESS, LLC | 2007-07-12 | — | — | US | claimed |
| US-20040063870-A1 | Curable epoxy-based compositions | LOCTITE (R&D) LTD. | 2004-04-01 | — | — | US | claimed |
| US-6653371-B1 | Shelf life stability | BURNS BARRY E (IE) | 2003-11-25 | — | — | US | claimed |
| EP-1047744-B1 | CURABLE EPOXY-BASED COMPOSITIONS | LOCTITE R & D LTD (IE) | 2002-10-02 | — | — | EP | claimed |
| EP-1047744-A1 | CURABLE EPOXY-BASED COMPOSITIONS | Loctite (R & D) Limited (IE) | 2000-11-02 | — | — | EP | claimed |
| WO-1999036484-A1 | CURABLE EPOXY-BASED COMPOSITIONS | LOCTITE (R & D) LIMITED (IE) | 1999-07-22 | — | — | WO | claimed |
| US-11884850-B2 | Adhesive film including a (meth)acrylate matrix including a curable epoxy/thiol resin composition, tape, and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| CN-112494430-B | Preparation method of pharmaceutical composition and pharmaceutical composition | 芬欧汇川集团 | 2023-06-02 | — | — | CN | disclosed |
| CN-115927442-A | Soybean transformation event TL107 and detection method and application thereof | 上海交通大学 | 2023-04-07 | — | — | CN | disclosed |
| US-20040063870-A1 | Curable epoxy-based compositions | LOCTITE (R&D) LTD. | 2004-04-01 | — | — | US | disclosed |
| US-6653371-B1 | Shelf life stability | BURNS BARRY E (IE) | 2003-11-25 | — | — | US | disclosed |
| EP-1047744-B1 | CURABLE EPOXY-BASED COMPOSITIONS | LOCTITE R & D LTD (IE) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070160688-A1 | Use of flavonoids to increase blood serum levels of dehydroepiandrosterone | SHBG, CYP17A1, HSD17B11 | PLK1 2012/4885MEN1 2514/4885MAPT 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.